Skip to main
MRUS
MRUS logo

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 19 analyst ratings
Strong Buy
Strong Buy 63%
Buy 32%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV's stock outlook appears positive due to its innovative pipeline of bispecific antibody therapeutics, with particular emphasis on promising data from the Phase 2 trial showing a potential for best-in-class efficacy. The company has de-risked its ongoing Phase 3 trials through FDA endorsement of trial design and has received breakthrough therapy designation for key indications, which could enhance the probability of successful commercialization. Additionally, the encouraging efficacy signals from related therapies in the market support the scientific rationale for Merus's products, positioning the company favorably in a competitive landscape.

Bears say

The financial outlook for Merus NV is hindered by low visibility regarding the success of its lead clinical trial, the LiGeR-HN1, which is essential for demonstrating overall survival (OS) benefits in future Phase 3 studies. The company's products face various risks, including potential regulatory and commercial setbacks, competitive pressures from emerging therapies, and the possibility of reduced sales accompanied by dilutive financing that exceeds current assumptions. Additionally, the data supporting the efficacy of Merus's bispecific antibody candidates, particularly the “ficera” dataset, appears less compelling compared to competitors, further contributing to an unfavorable risk-reward profile.

Merus (MRUS) has been analyzed by 19 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 32% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Strong Buy based on their latest research and market trends.

According to 19 analysts, Merus (MRUS) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.